A DIVERSE, TALENTED TEAM UNITED IN IMPROVING PATIENT OUTCOMES
THE SETPOINT MEDICAL STORY
SetPoint Medical is a privately held biomedical technology company located in Valencia, CA. The company focuses exclusively on developing bioelectronic medicine therapies to treat patients with debilitating autoimmune diseases. The company is pioneering a new treatment paradigm, using electrical pulses that activate the body’s innate “Inflammatory Reflex,” for rheumatoid arthritis, Crohn’s disease and other chronic autoimmune diseases as a safe, cost-effective alternative to drugs and biologics.
Founded in 2007, SetPoint Medical started exploring the scientific principles of stimulating the vagus nerve for treatment of autoimmune diseases based on Dr. Kevin Tracey’s pioneering discovery of the Inflammatory Reflex. In 2011, SetPoint Medical initiated proof-of-concept studies for treating rheumatoid arthritis using a modified off-the-shelf vagus nerve stimulator. The successful results of this study were published in the esteemed Proceedings of the National Academy of Sciences. SetPoint then closed Series C funding, to accelerate the development of its bioelectronic platform.
SetPoint Medical’s first-of-its-kind, miniaturized pulse generator is currently undergoing clinical studies in the United States for rheumatoid arthritis under FDA’s Investigational Device Exemption. In parallel, the company has conducted an additional successful proof-of-concept study in Crohn’s disease as well as promising pre-clinical research in multiple sclerosis. SetPoint Medical expects to commercialize its bioelectronic medicine platform in the coming years following FDA approval for treatment of inflammation-mediated autoimmune diseases.
JOIN THE TEAM
For those who have a passion for developing the
next major frontier in medicine, SetPoint Medical offers a fun, fast-paced, modern work environment with excellent benefits.
For Media Information Contact firstname.lastname@example.org
August 24, 2018
March 20, 2017
September 8, 2015
SetPoint Medical Announces U.S. Pilot Trial to Evaluate First Bioelectronic Device to Treat Rheumatoid Arth...Read Press Release from
March 26, 2018